|
|
Vaccine Detail
|
ONYX-015 Vaccine |
| Vaccine Information |
- Vaccine Name: ONYX-015 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007029
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: p53
- human TP53 (P53)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: ONYX-015 (CI-1042) is a modified adenovirus that carries a loss-of-function mutation at the E1B locus, the product of which is a 55 kDa protein that binds to and inactivates the p53 tumor suppressor protein (Cohen and Rudin, 2001).
- Description: This is for Lip and Oral Cavity Cancer, Head and Neck Cancer and Oropharyngeal Cancer (NCT00006106). An E1B-55kDa-deleted adenovirus that is able to selectively replicate in and lyse TP53-deficient human tumor cells. After tumor cell lysis, released viruses infect neighboring tumor cells, tripping a chain of ONYX-015-mediated tumor cell cytotoxicity. (NCI04) (Cohen and Rudin, 2001; NCIT_C2830).
|
| Host Response |
|
|
| References |
Cohen and Rudin, 2001: Cohen EE, Rudin CM. ONYX-015. Onyx Pharmaceuticals. Current opinion in investigational drugs (London, England : 2000). 2001; 2(12); 1770-1775. [PubMed: 11892945].
NCIT_C2830: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2830]
NCT00006106: [https://clinicaltrials.gov/ct2/show/NCT00006106?term=ONYX-015&rank=1]
|
|
